Felix Yeh - JoVE Visualize

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Filters

Felix Yeh

Showing results (1-10 of 3) with videos related to

Pageof 1

Sort By:

Science (New York, N.Y.)|March 18, 2006

SV2 is the protein receptor for botulinum neurotoxin AMin Dong, Felix Yeh, William H Tepp, et al.

Journal of Translational Medicine|June 15, 2023

Latozinemab, a novel progranulin-elevating therapy for frontotemporal dementiaMichael Kurnellas, Ananya Mitra, Tina Schwabe, et al.

Alzheimer'S Research & Therapy|October 24, 2024

Preclinical and first-in-human evaluation of AL002, a novel TREM2 agonistic antibody for Alzheimer's diseaseHua Long, Adam Simmons, Arthur Mayorga, et al.

Pageof 1

Search research articles

Showing results (1-10 of 3) with videos related to

Sort By:

Pageof 1

Science (New York, N.Y.)|March 18, 2006

SV2 is the protein receptor for botulinum neurotoxin AMin Dong, Felix Yeh, William H Tepp, et al.

Journal of Translational Medicine|June 15, 2023

Latozinemab, a novel progranulin-elevating therapy for frontotemporal dementiaMichael Kurnellas, Ananya Mitra, Tina Schwabe, et al.

Alzheimer'S Research & Therapy|October 24, 2024

Preclinical and first-in-human evaluation of AL002, a novel TREM2 agonistic antibody for Alzheimer's diseaseHua Long, Adam Simmons, Arthur Mayorga, et al.

Pageof 1